Pre-Open Stock Movers 01/13: (PRWM) (MBOT) (JILL) Higher; (SSI) (INGN) (FIVE) Lower (more...)

Today's Pre-Open Stock Movers

Stage Stores, Inc. (NYSE: SSI)53.7% LOWER; today reported comparable sales for the holiday period. For the nine-week period ended January 4, 2020, comparable sales increased 1.4% as compared to the nine-week period ended January 5, 2019.1 For the 48-week year to date period, comparable sales increased 4.2%... now expect full year 2019 earnings to be approximately $25 million to $30 million below the low end of the previously announced guidance range.

Primo Water Corporation (Nasdaq: PRMW)25.7% HIGHER; Cott Corporation (NYSE: COT) today announced that it has entered into a definitive agreement pursuant to which Cott will acquire Primo Water Corporation (Nasdaq: PRMW) (Primo) for $14.00 per share payable in cash and stock (or a combination thereof) at the election of Primos stockholders, subject to the terms of the merger agreement. The transaction, which values Primo at approximately $775 million, was unanimously approved by both the Cott and Primo Boards of Directors. Primo is a leading provider of water dispensers, purified bottled water, and self-service refill drinking water in the U.S. and Canada.

Inogen, Inc. (NASDAQ: INGN)23.2% LOWER; Total fourth quarter 2019 revenue is expected to be in the range of $78.4 to $79.4 million based on preliminary, unaudited financial data, down 8.2% to 9.4% from the same period in 2018. (*Consensus sees Q4 revenue of $89.96 million and FY19 revenue of $372.96 million. FY20 revenue is seen at $411.23 million).

Five Below, Inc. (NASDAQ: FIVE)19.9% LOWER; announced net sales results for the quarter-to-date period from November 3, 2019 through January 4, 2020. The Company announced that net sales for the Holiday Period increased by 13.4% to $596.6 million from $526.1 million in the comparable nine-week period from November 4, 2018 to January 5, 2019. Comparable sales for the Holiday Period decreased by 2.6%. Sees Q4 Net sales of $685 million to $688 million and Diluted income per common share of $1.93 to $1.96 (Consensus sees Q4 EPS of $2.02 on revenue of $728.8 million).

Microbot Medical (NASDAQ: MBOT)17% HIGHER; H.C. Wainwright analyst Raghuram Selvaraju raised the price target on to $26.00 (from $12.00) while maintaining a Buy rating. The analyst commented, "Microbot Medical is publicly demonstrating the worlds first fully disposable LIBERTY robotic system for use in all endovascular procedures during the J.P. Morgan Healthcare Conference in San Francisco, CA..."

J.Jill (NYSE: JILL)15% HIGHER; announced that the Company is updating its sales and earnings guidance for the fourth quarter of fiscal 2019 ending February 1, 2020, in advance of management’s meetings at the ICR Conference. For the fourth quarter of fiscal 2019, the Company now expects total comparable sales to decrease 6% to 8% with total net sales expected to decrease 3% to 5%. This compares to the previous guidance for total comparable sales to decrease 8% to 10% with total net sales expected to decrease 5% to 7%. The Company now expects earnings per share to be a loss of $0.10 to $0.12. This compares to the previous guidance for earnings per share to be a loss of $0.14 to $0.16.

The Lovesac Company (Nasdaq: LOVE)13.2% LOWER; updated its outlook for fiscal 2020 ahead of its participation at the ICR conference.

Assertio Therapeutics (Nasdaq: ASRT)12.6% HIGHER; Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior Guidance

TerraForm Power, Inc. (Nasdaq: TERP)9.7% HIGHER; confirmed that on January 11, 2020, its Board of Directors (the Board) received an unsolicited, non-binding proposal (the Proposal) from Brookfield Renewable Partners L.P. (NYSE: BEP) (Brookfield Renewable) to acquire all of the outstanding shares of Class A common stock of TerraForm Power, other than the approximately 62% of TerraForm Powers shares currently held by Brookfield Renewable and its affiliates (the proposed transaction). Pursuant to the Proposal, each share of Class A common stock of TerraForm Power would be acquired for consideration of 0.36 of a Class A share of Brookfield Renewable Corporation (BEPC). The Proposal states that BEPC is a Canadian subsidiary of Brookfield Renewable and will be a publicly traded corporation. The Proposal further states that BEPC's Class A shares will be structured to be economically equivalent to Brookfield Renewable units and will be fully exchangeable, on a one-for-one basis, into units of Brookfield Renewable.

3D Systems (NYSE: DDD)6.3% HIGHER; Craig-Hallum upgraded from Hold to Buy with a price target of $14.00.

Hexcel Corporation (NYSE: HXL)6.2% HIGHER; Woodward, Inc. (NASDAQ: WWD) and Hexcel Corporation (NYSE: HXL) today announced a definitive agreement to combine in an all-stock merger of equals to create a premier integrated systems provider serving the aerospace and industrial sectors. The combined company will focus on technology-rich innovations to deliver smarter, cleaner, and safer customer solutions.

CEL-SCI (NYSE: CVM)6% HIGHER; H.C. Wainwright initiates coverage on with a Buy rating and a price target of $18.00.

Lannett Company, Inc. (NYSE: LCI)5.8% HIGHER; today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA), submitted under the 505(b)(2) regulatory pathway, for Cocaine Hydrochloride (HCl) Nasal Solution 4% (40 mg/mL), the company's branded local anesthetic product.

Karyopharm Therapeutics Inc. (NASDAQ: KPTI)5.4% HIGHER; announced preliminary unaudited fourth quarter and full year 2019 net product sales for XPOVIO® (selinexor), the Companys first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, and provided additional updates on the products commercial launch.

Horizon Therapeutics plc (Nasdaq: HZNP)3.8% HIGHER; announced today topline results from its MIRROR open-label study in which methotrexate with KRYSTEXXA® (pegloticase injection) provided an increased durability of response for people living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.